ReviewFrontiers in microbiology2015
Heterologous production of fungal secondary metabolites in Aspergilli.
Review in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 90 citations in OpenAlex.
- One-step in vivo assembly of a 63 kb-long biosynthetic gene cluster via multiple recombination in Aspergillus oryzae.Applied microbiology and biotechnology · 2026Article
- Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.Heliyon · 2024Review
- Construction of a Cosmid-Based Ultraefficient Genomic Library System for Filamentous Fungi of the GenusJournal of fungi (Basel, Switzerland) · 2024Article
- Computer-aided, resistance gene-guided genome mining for proteasome and HMG-CoA reductase inhibitors.Journal of industrial microbiology & biotechnology · 2023Article
- Biotechnological Fungal Platforms for the Production of Biosynthetic Cannabinoids.Journal of fungi (Basel, Switzerland) · 2023Review
- Total Heterologous Biosynthesis of Fungal Natural Products inJournal of natural products · 2022Review
- Endophytic Fungi: Key Insights, Emerging Prospects, and Challenges in Natural Product Drug Discovery.Microorganisms · 2022Review
- FunOrder 2.0 - a method for the fully automated curation of co-evolved genes in fungal biosynthetic gene clusters.Frontiers in fungal biology · 2022Article
- Physiological limitations and opportunities in microbial metabolic engineering.Nature reviews. Microbiology · 2022Review
- Transcriptional Activation of Biosynthetic Gene Clusters in Filamentous Fungi.Frontiers in bioengineering and biotechnology · 2022Review
- Heterologous Expression of Fungal Biosynthetic Pathways in Aspergillus nidulans Using Episomal Vectors.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Investigating Fungal Biosynthetic Pathways Using Heterologous Gene Expression: Aspergillus nidulans as a Heterologous Host.Methods in molecular biology (Clifton, N.J.) · 2022Article
- FunOrder: A robust and semi-automated method for the identification of essential biosynthetic genes through computational molecular co-evolution.PLoS computational biology · 2021Article
- Natural products in drug discovery: advances and opportunities.Nature reviews. Drug discovery · 2021Review
- Deep learning approaches for natural product discovery from plant endophytic microbiomes.Environmental microbiome · 2021Review
- Secondary metabolites from hypocrealean entomopathogenic fungi: genomics as a tool to elucidate the encoded parvome.Natural product reports · 2020Review
- Recent Discovery of Heterocyclic Alkaloids from Marine-DerivedMarine drugs · 2020Review
- Genetic platforms for heterologous expression of microbial natural products.Natural product reports · 2019Review
- Date Palm Trees Root-Derived Endophytes as Fungal Cell Factories for Diverse Bioactive Metabolites.International journal of molecular sciences · 2018Article
- Omics based approach for biodiscovery of microbial natural products in antibiotic resistance era.Journal, genetic engineering & biotechnology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal natural products comprise a wide range of compounds. Some are medically attractive as drugs and drug leads, some are used as food additives, while others are harmful mycotoxins. In recent years the genome sequence of several fungi has become available providing genetic information of a large number of putative biosynthetic pathways. However, compound discovery is difficult as the genes required for the production of the compounds often are silent or barely expressed under laboratory conditions. Furthermore, the lack of available tools for genetic manipulation of most fungal species hinders pathway discovery. Heterologous expression of the biosynthetic pathway in model systems or cell factories facilitates product discovery, elucidation, and production. This review summarizes the recent strategies for heterologous expression of fungal biosynthetic pathways in Aspergilli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.